RTP Mobile Logo
Meet The Professor: Current and Future Management of Myelofibrosis — Part 3 of a 3-Part Series (Webinar Video Proceedings)
Released June 2022

Featuring perspectives from Dr John Mascarenhas. Published June 16, 2022. (Webinar Video Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of myelofibrosis.

    LEARNING OBJECTIVES

    • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis (MF).
    • Appreciate the FDA approval of fedratinib for intermediate-2 or high-risk primary or secondary MF, and identify patients for whom treatment with this agent is appropriate.
    • Assess the tolerability profiles of ruxolitinib and fedratinib, and formulate a side-effect management plan to support quality of life and continuation of treatment.
    • Understand the mechanism of action of and available clinical research data with pacritinib for patients with MF and severe thrombocytopenia in preparation for the potential availability of this novel therapeutic approach.
    • Appraise available and emerging clinical trial findings with momelotinib for patients with MF, including those with disease-related anemia, and discern the role this agent may have in the disease-management paradigm.
    • Recall the biologic rationale for the design of ongoing clinical trials evaluating novel investigational agents and strategies for MF, and refer eligible patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: CME credit is no longer available for this issue

    Video Program: CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    John Mascarenhas, MD
    Director, Adult Leukemia Program
    Professor of Medicine
    Tisch Cancer Institute
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Advisory Committee: Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Geron, Incyte Corporation, Novartis, Roche Laboratories Inc, PharmaEssentia, Sierra Oncology; Consulting Agreements: Celgene Corporation, CTI BioPharma Corp, Kartos Therapeutics, Karyopharm Therapeutics; Contracted Research: AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, CTI BioPharma Corp, Geron, Incyte Corporation, Kartos Therapeutics, Novartis, Roche Laboratories Inc, PharmaEssentia; Data and Safety Monitoring Board/Committee: Galecto.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from CTI BioPharma Corp and Incyte Corporation.

    Release date: June 2022
    Expiration date: June 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):